European Prostate Cancer Awareness Day
3 September 2025 Register here

Homepage

Calling on the EU to implement improved, risk-based PCa screening

In Northern and Western Europe, prostate cancer is either the leading or second leading cause of cancer death in men. It is the most frequently occurring male cancer in Europe that has important consequences for healthcare systems. Most European countries already have screening programmes for cervical, breast and colorectal cancer.

After 20 years, in 2022 the Council of the European Union updated its Cancer Screening Recommendations, which now include prostate cancer.

There is good evidence that organised prostate cancer screening using PSA tests in steps works well, especially when it is followed by other tests like MRI (Magnetic Resonance Imaging).

To join EPAD25, please register your interest here.

Register here

Incidence

Every year, around 450,000 European men are diagnosed with prostate cancer. It has overtaken colorectal cancer.

Mortality

107,000 European men die of prostate cancer each year. The cancer kills more men than breast cancer kills women.

Costs

The yearly costs of PCa in Europe are 9 billion euros, with healthcare accounting for 5.8 billion euros.

The EPAD25 partners